Insider buying last 90 days
No open-market insider purchases were filed for CHE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CHE insider filing, plotted on the chart in Gekko.Open CHE in Gekko
Gekko Brief
AI summaryUBS initiated coverage on Chemed with a Buy rating and a $650 price target, citing expectations for 19% EPS growth in 2026 followed by 10% in 2027 and 2028, driven by EBITDA growth and share repurchases. Separately, Chemed's Roto-Rooter unit acquired its largest independent franchise, covering California territories serving approximately 11 million people, for $60.6 million. Chemed CEO Kevin McNamara also sold 2,000 shares on 18 September 2026 at an average price of $501.40, retaining 68,418 shares.
Chemed closed at $514.30, up 0.4%, sitting between its 50-day average of $523.31 and 200-day average of $453.56, with a 1-month return of -1.1% against a 6-month gain of 39.5%. The GekkoIndex reads 56.7, placing the stock in the Neutral zone after a five-point decline of -12.6 over the past five sessions. Price sits 5.5% below Gekko Fair Value of $544.00.
Chemed next reports earnings on 27 October 2026, 28 days out and within a typical 20-trading-day holding window; its last report on 28 July 2026 saw EPS of $6.06 against an estimate of $5.60, with a 5.9% reaction, and it has beaten estimates in 4 of the last 8 quarters. No insider, Congress or unusual options activity registered in their respective windows. Seasonally, the next 20 trading days have averaged a 0.7% return over 5 years, rising in 3 of them. Consensus among 3 firms stands at 1 buy and 2 hold, with a consensus target of $571.60.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Chemed price vs fair value
Close $514.30200-day averageGekko Fair Value $544.00
Chemed quick facts
- Market cap
- $6.72B
- P/E ratio
- 25.8
- Forward P/E
- 18.2
- EPS, TTM
- $19.87
- Revenue, TTM
- $2.60B
- Profit margin
- 10.6%
- Dividend yield
- 0.48%
- Beta
- 0.51
- Volume
- 215,995 avg 148,851
- 1-year return
- +14.2%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±3.8%
- 50-day average
- $523.31
- 200-day average
- $453.56
- Next earnings
- Oct 27
- Shares outstanding
- 13.07M
Chemed swing-trade checklist
Chemed scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $514.30 sits between the 50-day ($523.31) and 200-day ($453.56) averages, or the averages disagree.
See the chart - GekkoIndexmixed
56.7, Neutral
Reading 56.7 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
5.5% below
Price is 5.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Oct 27, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Chemed stock chart and price history
Chemed closed at $514.30 on Sep 28, 2026, +14.2% over the past year, inside a 52-week range of $365.21 to $557.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.1%
- 3 months
- +11.8%
- 6 months
- +39.5%
- 1 year
- +14.2%
The full CHE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CHE in Gekko
Follow Chemed through every session
Put CHE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CHE in GekkoFree for 7 days. No credit card required.
About Chemed
Chemed brings together support for people in the final stages of illness, pairing medical treatment with emotional and spiritual comfort for patients and the families around them. The work is carried out by a mix of physicians, nurses, aides, social workers, clergy and volunteers. The company is also active in a completely different trade, fixing pipes, clearing drains, digging excavations and repairing water damage for homes and businesses.
These two very different activities sit under separate arms of the business, VITAS and Roto-Rooter. VITAS focuses on hospice and palliative care, largely within the United States, while Roto-Rooter reaches its customers through branches it owns directly as well as independent contractors and franchise partners, covering both households and commercial clients.
Founded in 1970, Chemed is based in Cincinnati, Ohio, and its stock trades on the NYSE under the ticker CHE.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Website
- chemed.com
Chemed GekkoIndex: the smart money zone
Chemed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.7, in the Neutral zone, down 12.6 points over five sessions.
56.7Neutral
Down 12.6 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | +0.8% | −0.2% | ||
| Accumulation | 255 | −0.1% | 0.0% | ||
| Neutral (current zone) | 344 | −0.2% | −0.4% | ||
| Distribution | 33 | +0.4% | +0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average CHE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CHE price, zone by zone.Track CHE in Gekko
Is Chemed stock overvalued? Gekko Fair Value
Chemed trades 5.5% below Gekko Fair Value of $544.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Chemed shares are worth, recalculated every trading day.
$544.00
Gekko Fair Value, Sep 29, 2026
5.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CHE in Gekko
Chemed insider and Congress trading
No open-market insider purchases were filed for Chemed, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CHE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CHE, plotted on the chart in Gekko.Open CHE in Gekko
Buybacks
Chemed has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $97.48M
- As a share of market cap
- 1.45%
- Trailing four quarters
- $642.9M
From company filings.
Chemed earnings: next date and track record
Chemed reports on Oct 27, 2026 (28 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Oct 27, 2026
28 days away
- EPS estimate
- $6.39
- Revenue estimate
- $685.0M
4 of 8reports beat the EPS estimate
±7.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 28, 2026 AI summary
- What they said
- VITAS Healthcare exceeded high-end expectations in Q2 2026, with admissions of 19,125 (up 9% YoY) and higher-than-expected revenue growth and EBITDA margins while adding $8.9M to Florida cap cushion. Roto-Rooter showed mixed results: commercial revenue grew 6.8% YoY with commercial business manager branches up 13%, but marketing costs rose $3.1M due to declining free leads (-13.1%) and rising paid leads (59% of total vs. 54% prior year). Roto-Rooter acquired south Texas franchise assets for ~$12M.
- Guidance
- Management expressed increased confidence that VITAS has returned to normalized growth following the 2025 Florida cap issue. No specific revenue or EPS targets were provided in this excerpt, but tone suggests continued expansion of commercial business manager program at Roto-Rooter.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $6.06 est $5.60 | $673.3M est $665.0M | +5.9% |
| Apr 23, 2026 | $5.65 est $5.30 | $657.5M est $649.8M | +12.9% |
| Oct 28, 2025 | $5.27 est $5.39 | $624.9M est $659.0M | +6.6% |
| Jul 29, 2025 | $4.27 est $4.78 | $618.8M est $631.1M | −10.6% |
| Apr 23, 2025 | $5.63 est $5.55 | $646.9M est $641.8M | −5.6% |
| Feb 26, 2025 | $6.83 est $6.78 | $640.0M est $636.1M | +6.4% |
| Oct 29, 2024 | $5.64 est $5.76 | $606.2M est $636.1M | −12.0% |
| Jul 24, 2024 | $5.47 est $5.59 | $595.9M est $599.2M | −0.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Chemed stock forecast and analyst price targets
Analysts’ average 12-month price target for Chemed is $571.60, +11.1% from the last close, from 3 firms rating the stock in the last 90 days.
$571.60consensus 12-month target, +11.1% from the last close
Now $514.30Avg $571.60
Low $548High $590
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 16 | Bank of America Securities | $550 | +6.9% |
| Jul 31 | Oppenheimer | $590 | +14.7% |
| Jul 30 | RBC Capital | $548 | +6.6% |
| Jul 29 | Bank of America Securities | — | — |
| Jul 9 | Bank of America Securities | $510 | −0.8% |
−0.4%average 20-day move after past Neutral readings
+0.7%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Chemed seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Chemed averaged +0.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.4% | 0 of 5 |
| Next 10 trading days | −4.9% | 0 of 5 |
| Next 15 trading days | −1.1% | 2 of 5 |
| Next 20 trading days | +0.7% | 3 of 5 |
| Next 30 trading days | +4.0% | 3 of 5 |
For scale, CHE’s typical 20-trading-day move in either direction is about 3.8%.
Chemed market cap and key statistics
Chemed’s market cap is $6.72B, with a P/E ratio of 25.8 and revenue of $2.60B over the last twelve months.
Valuation
- Market cap
- $6.72B
- P/E ratio
- 25.8
- Forward P/E
- 18.2
- EPS, TTM
- $19.87
- Gekko Fair Value
- $544.00
Trading
- Volume
- 215,995
- Avg volume, 20 days
- 148,851
- 52-week high
- $557.00
- 52-week low
- $365.21
- Shares outstanding
- 13.07M
Financials
- Revenue, TTM
- $2.60B
- Profit margin
- 10.6%
- Return on equity
- 27.1%
- Quarterly earnings growth, YoY
- +43.7%
Risk and income
- Beta
- 0.51
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±3.8%
- Dividend yield
- 0.48%
Chemed stock news this week
Coverage of Chemed this week reads positive: 5 positive, 3 neutral and 4 negative headlines.
- CHE Initiates Coverage by UBS -- Price Target Announced at $650GuruFocus, Sep 25
- Chemed Corp (CHE) Stock Up 3.3% and Still Undervalued -- GF ScorGuruFocus, Sep 25
- UBS initiates Chemed stock coverage with buy rating on growth outlookInvesting.com UK, Sep 25
- Form 144 CHEMED CORP For: 24 September By Investing.comInvesting.com UK, Sep 24
- Corient Private Wealth LP Increases Stock Position in Chemed Corporation $CHEDefense World, Sep 23
- Chemed (CHE) Buys a $60.6M Roto-Rooter Franchise. Can Ownership Lift Returns?Insider Monkey, Sep 22
Chemed peers
Chemed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| HCAHCA Healthcare | Neutral | 12.8% above |
| THCTenet Healthcare | Neutral | 9.4% below |
| UHSUniversal Health Services | Neutral | 20.1% below |
| PACSPACS | Accumulation | 14.2% below |
| NHCNational HealthCare | Neutral | 29.0% above |
| BKDBrookdale Senior Living | Buying | 11.8% below |
A peer links to its own page where one exists.
Chemed stock FAQ
What is Chemed’s market cap?
Chemed’s market cap is $6.72B at the Sep 28, 2026 close of $514.30, with 13.07M shares outstanding. The shares trade on a P/E ratio of 25.8.
What is the Chemed stock forecast?
The consensus analyst 12-month price target for Chemed is $571.60, +11.1% from the last close. Of the 3 firms that rated the stock in the last 90 days, 1 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Chemed stock overvalued or undervalued?
On Gekko’s estimate Chemed is undervalued: the Sep 28, 2026 close of $514.30 is 5.5% below Gekko Fair Value of $544.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Chemed report earnings next?
Chemed is expected to report on Oct 27, 2026 (28 days away). Analysts expect earnings of $6.39 per share on revenue of $685.0M. Chemed beat the earnings estimate in 4 of its last 8 reports, moving 7.5% on average across the report.
What is Chemed’s 52-week high and low?
Chemed’s 52-week high is $557.00 and its 52-week low is $365.21; it closed at $514.30 on Sep 28, 2026, +14.2% over the past year. Over the last five years the shares peaked at $654.62 on Mar 15, 2024.
Is Chemed stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Chemed the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.